Active	Status	Sponsor type	Region	Phase	Filter
13 Active 7 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pal, Sumanta
NCT05406713: Pembrolizumab in Muscle-invasive Bladder Cancer	Recruiting	2	46	US	Pembrolizumab, Keytruda	Matthew Galsky, Merck Sharp & Dohme LLC	Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma	01/27	01/28
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies	Active, not recruiting	1	40	Europe, Japan, US, RoW	DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant	Novartis Pharmaceuticals	Carcinoma, Renal Cell	09/25	09/25